UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ambient temperature light-off for automobile emission control

Applied catalysis. B, Environmental, 1998-09, Vol.18 (1-2), p.123-135

1998

Volltextzugriff (PDF)

Effects of SO2 on the alkane activity of three-way catalysts

Catalysis letters, 1991-03, Vol.11 (2), p.183-190

1991

Volltextzugriff (PDF)

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

Journal of clinical oncology, 2018-05, Vol.36 (14), p.1428-1439

2018

Volltextzugriff (PDF)

Heat and moisture transfer behaviour in Phyllostachys edulis (Moso bamboo) based panels

Construction & building materials, 2018-03, Vol.166, p.35-49

2018

Volltextzugriff (PDF)

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Blood advances, 2023-10, Vol.7 (20), p.6266-6274

2023

Volltextzugriff (PDF)

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

The New England journal of medicine, 2010-12, Vol.363 (26), p.2487-2498

2010

Volltextzugriff (PDF)

Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells

Clinical cancer research, 2020-11, Vol.26 (21), p.5759-5771

2020

Volltextzugriff (PDF)

IRF4 Rewires Tumor Metabolism with Functional Implications on the Immune Microenvironment in Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.1643-1643

2023

Volltextzugriff (PDF)

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Blood advances, 2024-05, Vol.8 (10), p.2400-2404

2024

Volltextzugriff (PDF)

Re-resection of Microscopically Positive Margins Found on Intraoperative Frozen Section Analysis Does Not Result in a Survival Benefit in Patients Undergoing Surgery and Intraoperative Radiation Therapy for Locally Recurrent Rectal Cancer

Diseases of the colon & rectum, 2022-09, Vol.65 (9), p.1094-1102

2022

Volltextzugriff (PDF)

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Blood, 2020-11, Vol.136 (Supplement 1), p.21-23

2020

Volltextzugriff (PDF)

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Blood, 2022-11, Vol.140 (Supplement 1), p.3673-3677

2022

Volltextzugriff (PDF)

A genome-wide association study of marginal zone lymphoma shows association to the HLA region

Nature communications, 2015-01, Vol.6 (1), p.5751, Article 5751

2015

Volltextzugriff (PDF)

A Machine Learning Algorithm to Identify Patients at Risk of Unplanned Subsequent Surgery After Intramedullary Nailing for Tibial Shaft Fractures

Journal of orthopaedic trauma, 2021-10, Vol.35 (10), p.e381-e388

Machine Learning Consortium on behalf of the SPRINT Investigators

2021

Volltextzugriff (PDF)

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.2932-2932

2018

Volltextzugriff (PDF)

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.2897-2897

2018

Volltextzugriff (PDF)

A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS7573-TPS7573

2016

Volltextzugriff (PDF)

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7539-7539

2018

Volltextzugriff (PDF)

Impact of centre volume, surgeon volume, surgeon experience and geographic location on reoperation after intramedullary nailing of tibial shaft fractures

Canadian Journal of Surgery, 2021-07, Vol.64 (4), p.E371-E376

2021

Volltextzugriff (PDF)

Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS7575-TPS7575

2017

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)
Buchkapitel
(1)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ambient temperature light-off for automobile emission control

Effects of SO2 on the alkane activity of three-way catalysts

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

Heat and moisture transfer behaviour in Phyllostachys edulis (Moso bamboo) based panels

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells

IRF4 Rewires Tumor Metabolism with Functional Implications on the Immune Microenvironment in Lymphoma

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Re-resection of Microscopically Positive Margins Found on Intraoperative Frozen Section Analysis Does Not Result in a Survival Benefit in Patients Undergoing Surgery and Intraoperative Radiation Therapy for Locally Recurrent Rectal Cancer

Safety and Preliminary Efficacy of Sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-(L)1 Therapy

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Oral Abstract: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Poster: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

A genome-wide association study of marginal zone lymphoma shows association to the HLA region

A Machine Learning Algorithm to Identify Patients at Risk of Unplanned Subsequent Surgery After Intramedullary Nailing for Tibial Shaft Fractures

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS)

Impact of centre volume, surgeon volume, surgeon experience and geographic location on reoperation after intramedullary nailing of tibial shaft fractures

Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Suchergebnisse filtern